Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.99
+0.01 (0.04%)
Dec 5, 2025, 4:00 PM EST - Market closed
Pacira BioSciences Employees
As of December 31, 2024, Pacira BioSciences had 790 total employees, including 788 full-time and 2 part-time employees. The number of employees increased by 78 or 10.96% compared to the previous year.
Employees
790
Change (1Y)
78
Growth (1Y)
10.96%
Revenue / Employee
$907,330
Profits / Employee
$27,137
Market Cap
1.03B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PCRX News
- 3 days ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical - GlobeNewsWire
- 25 days ago - Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewsWire
- 25 days ago - DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business - PRNewsWire
- 4 weeks ago - Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance - GlobeNewsWire
- 4 weeks ago - Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee - GlobeNewsWire
- 4 weeks ago - Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control - GlobeNewsWire